The U.S. Patent and Trademark Office issued Cellectar Biosciences Inc. patent allowances for imaging agents delivered via the company's phospholipid drug conjugate platform.
The issued patent allowances cover method of use for CLR 124 in the detection of radiation- and chemo-insensitive cancer or cancer metastases. The allowed claims are a continuation in part of a U.S. patent with coverage extending until March 2, 2025.
Further, the Japanese Patent Office granted the oncology-focused biotechnology company a composition of matter allowance covering two optical imaging agents in the CLR 1500 series. These CLR 1500 compounds are from a divisional application with coverage extending through May 11, 2030.